IN VITRO METHODS FOR DETECTING RENAL CANCER

• Main Authors: SANZ IBAYONDO, CRISTINA, GOMEZ ROMAN, JOSE, JAVIER, DEL AMO IRIBARREN, JOKIN, OCHOA GARAY, JORGE, ARGUEELLES SANCHEZ, MARIA ELADIA, CUEVAS GONZALEZ, JORGE, JUNQUERA SANCHEZ-VALLEJO, CORINA, SIMON BUELA, LAUREANO, SAENZ, JIMENEZ, MARIA, PILAR, MARTINEZ MARTINEZ, ANTONIO, VAL BERNAL, JOSE FERNANDO
• Format: Patent
• Language: English; French
• Published: 13.01.2005
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression. La présente invention a trait à un procédé in vitro permettant la détection de la présence de cancer du rein chez un individu, la détermination du stade, la malignité ou sévérité dudit carcinome chez l'individu ou le contrôle de l'effet de la thérapie administrée à un individu atteint dudit cancer ; à la recherche, l'identification, le développement et l'évaluation de l'efficacité de composés pour la thérapie pour ledit cancer dans le but de développer de nouveaux médicaments, ainsi qu'à des agents induisant l'expression et/ou l'activité de la protéine Plexine-B1, ou à des agents d'inhibition des effets de la suppression de l'expression et/ou l'activité de la protéine Plexine-B1.